Our results are coherent with the findings by Isaksson et al. who reported an EGFR prevalence of 10% in the 519 NSCLC patients subjected to the first 1.5 years of treatment predictive MPS testing in our health care region (2015 to mid- 2016) [25]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.